Madrigal sees road to approval for NASH drug resmetirom
pharmaphorum
DECEMBER 20, 2022
That’s impressive, as it has proved exceedingly difficult for pharmacological therapies to show an impact on fibrosis in prior studies. Similarly, a one-stage or greater improvement in liver fibrosis was seen in 24% and 26% of the resmetirom groups, respectively, versus 14% of patients taking placebo.
Let's personalize your content